← All trials
NCT05967533
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2023
- Primary completion
- Jun 2, 2025
- Completion date
- Dec 31, 2025
- First posted
- Aug 1, 2023
- Last posted
- Aug 1, 2023
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, DavisLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of California, DavisOverall official - principal investigator
- University of California, DavisReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.